Stockscreener 앱 받기
140.98
0.31%
0.43
시간 외 거래:
140.78
-0.20
-0.14%
Biogen Inc 주식(BIIB)의 최신 뉴스
Sage lawsuit enforces standstill as board evaluates Biogen offer - BioWorld Online
BIOGEN TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS FEBRUARY 12, 2025 - Biogen | Investor Relations
Looking At Biogen's Recent Unusual Options Activity - Benzinga
Sage sues partner Biogen after unsolicited takeover offer - PharmaLive
Alzheimer's Drugs Market Growth: AbbVie, Amgen, and Biogen Pioneering New Therapeutic Solutions - openPR
Guardian Investment Management Sells 2,865 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Sax Wealth Advisors LLC Invests $337,000 in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Avanza Fonder AB Makes New Investment in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen Announces New Chief Accounting Officer Appointment - MSN
Sage sues Biogen after unsolicited takeover bid - pharmaphorum
BRIEF—Biogen sued by Sage after buyout offer - The Pharma Letter
Wedge Capital Management L L P NC Acquires 26,530 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says - MSN
Biogen (NASDAQ:BIIB) Sets New 52-Week LowHere's What Happened - MarketBeat
Biogen Beats Humana's RICO Suit Over MS Drug Scheme on Appeal - Bloomberg Law
Sage sues Biogen in wake of $469M buyout offer: report (BIIB:NASDAQ) - Seeking Alpha
Biogen, Eisai say injectable Alzheimer’s therapy granted FDA review - MSN
Alzheimer’s drugs eyed as next big obesity-like opportunity - The Keene Sentinel
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt - Benzinga
Biogen Sued by Neuroscience Company Sage After Buyout Offer (1) - Bloomberg Law
Biogen's Quarterly Earnings Preview: What You Need to Know - Nasdaq
Biogen's Quarterly Earnings Preview: What You Need To Know - Barchart
Biogen Inc. Announces Executive Changes Effective March 1, 2025 -January 15, 2025 at 08:00 am EST - Marketscreener.com
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates - Yahoo Finance
The Escalator: Lykos Therapeutics, Biogen, CMI Media Group and more - MM+M Online
Czech National Bank Acquires 1,923 Shares of Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Wedmont Private Capital Has $546,000 Stake in Biogen Inc. (NASDAQ:BIIB) - MarketBeat
Biogen stock at lowest level since February 2013 following J.P. Morgan presentation - MSN
Amyotrophic Lateral Sclerosis Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Treatment Outlook | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma, Brainstorm Cell - The Globe and Mail
Biogen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Short Interest in Biogen Inc. (NASDAQ:BIIB) Increases By 42.6% - MarketBeat
Biogen stock stays strong with Outperform rating as Oppenheimer highlights disciplined growth strategy - Investing.com India
Biogen appoints new Chief Accounting Officer - Investing.com
OIG raises concerns about accelerated approval deviations - BioWorld Online
At JPM, Biogen CEO tries to take down the deal temperature - BioPharma Dive
Biogen Inc. (BIIB) Appoints New Chief Accounting Officer - GuruFocus.com
Biogen Says It's 'Doubling Down' on Alzheimer's Disease at JPM - Precision Medicine Online
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders - Seeking Alpha
Under Pressure to Deal, Biogen Executives Deflect Urgency at JPM25 - BioSpace
JPM25 day two: Roche, Amgen, Merck, Lilly, and Biogen - PharmaLive
Dispatches From JPM, Biogen’s Sage Buyout Offer, Pfizer’s Obesity Play, More - BioSpace
Inspector General Questions FDA’s Accelerated Approval for Biogen, Sarepta Drugs - BioSpace
Biogen CEO Discusses Strategy to Rely on New Product Launches for GrowthNews and Statistics - IndexBox, Inc.
JPM25 Day Two: Roche, Amgen, Merck, Lilly and Biogen - BioSpace
Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug - PMLiVE
Biogen lays out three FDA decisions that could ramp up Alzheimer's drug launch - The Business Journals
Biogen CEO targets faster dementia treatment launch with new subcutaneous Leqembi optionCHOSUNBIZ - 조선비즈
Alport Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - Barchart
Biogen Looks Ahead With Confidence As New Products Take Charge - Finimize
JPM25: Biogen 'doubling down' on Alzheimer's in long bet - FirstWord Pharma
Biogen CEO sees no burning need for more acquisitions - Reuters.com
Biogen Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Sarepta, Biogen drugs with accelerated approval under fire in FDA report - Seeking Alpha
JPM25, Day 2: Biogen ready to stand its ground in Alzheimer's showdown, CEO says - FiercePharma
Biogen, Sarepta Quick Drug Approvals Show FDA Gaps, Report Says | Company Business News - Mint
Biogen (NASDAQ:BIIB) Reaches New 12-Month LowHere's What Happened - MarketBeat
Biogen stock touches 52-week low at $144.96 amid challenges - Investing.com
BRIEF—FDA accepts BLA for subcutaneous Leqembi - The Pharma Letter
This Biogen Insider Increased Their Holding In The Last Year - Simply Wall St
1.22%
1.72%
자본화:
|
볼륨(24시간):